FDA draft guidance on compounding animal drugs from bulk drug substances: a commentary
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2364-9534
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
FDA draft guidance on compounding animal drugs from bulk drug substances: a commentary ; volume:2 ; number:1 ; day:7 ; month:7 ; year:2016 ; pages:1-3 ; date:12.2016
AAPS open ; 2, Heft 1 (7.7.2016), 1-3, 12.2016
- Creator
-
Karara, Adel H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s41120-016-0007-0
- URN
-
urn:nbn:de:1111-2016071018716
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Karara, Adel H.
- SpringerLink (Online service)
Other Objects (12)
FDA drug approvals: Time Is money!
Investigating drug repositioning opportunities in FDA drug labels through topic modeling
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Do investors value the FDA orphan drug designation?
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA drug approvals: Time Is money!
Investigating drug repositioning opportunities in FDA drug labels through topic modeling
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Do investors value the FDA orphan drug designation?
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA drug approvals: Time Is money!
Investigating drug repositioning opportunities in FDA drug labels through topic modeling
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Do investors value the FDA orphan drug designation?
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA